BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kridin K. Emerging treatment options for the management of pemphigus vulgaris. Ther Clin Risk Manag 2018;14:757-78. [PMID: 29740210 DOI: 10.2147/TCRM.S142471] [Cited by in Crossref: 28] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Halil Yavuz I, Ozaydın Yavuz G. The role of pentraxin 3 in pemphigus vulgaris. Postepy Dermatol Alergol 2020;37:503-7. [PMID: 32994770 DOI: 10.5114/ada.2019.81234] [Reference Citation Analysis]
2 Moussaoui E, Oueslati Y, Oualha L, Denguezli M, Sriha B, Douki N. Simultaneous Oral and Umbilical Locations as a First Sign of Pemphigus Vulgaris. Case Rep Dent 2021;2021:7792360. [PMID: 34733562 DOI: 10.1155/2021/7792360] [Reference Citation Analysis]
3 Didona D, Maglie R, Eming R, Hertl M. Pemphigus: Current and Future Therapeutic Strategies. Front Immunol 2019;10:1418. [PMID: 31293582 DOI: 10.3389/fimmu.2019.01418] [Cited by in Crossref: 57] [Cited by in F6Publishing: 46] [Article Influence: 19.0] [Reference Citation Analysis]
4 Stevens NE, Cowin AJ, Kopecki Z. Skin Barrier and Autoimmunity-Mechanisms and Novel Therapeutic Approaches for Autoimmune Blistering Diseases of the Skin. Front Immunol 2019;10:1089. [PMID: 31156638 DOI: 10.3389/fimmu.2019.01089] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
5 Jin X, Rosenbohm J, Kim E, Esfahani AM, Seiffert-Sinha K, Wahl JK 3rd, Lim JY, Sinha AA, Yang R. Modulation of Mechanical Stress Mitigates Anti-Dsg3 Antibody-Induced Dissociation of Cell-Cell Adhesion. Adv Biol (Weinh) 2021;5:e2000159. [PMID: 33724731 DOI: 10.1002/adbi.202000159] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Domínguez-Franco A, Méndez-Flores S, Ramírez-Marín HA, Olvera-Rodriguez V, Domínguez-Cherit JG. Pain Management in Patients with Severe Pemphigus Vulgaris. J Pain Palliat Care Pharmacother 2021;:1-5. [PMID: 34519607 DOI: 10.1080/15360288.2021.1963906] [Reference Citation Analysis]
7 van Beek N, Zillikens D, Schmidt E. [Therapy of pemphigus]. Hautarzt 2019;70:243-53. [PMID: 30887081 DOI: 10.1007/s00105-019-4385-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 Popescu IA, Statescu L, Vata D, Porumb-Andrese E, Patrascu AI, Grajdeanu IA, Solovastru LG. Pemphigus vulgaris - approach and management. Exp Ther Med 2019;18:5056-60. [PMID: 31819769 DOI: 10.3892/etm.2019.7964] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
9 Kridin K, Jones VA, Patel PM, Zelber-Sagi S, Hammers CM, Damiani G, Amber KT, Cohen AD. Patients with pemphigus are at an increased risk of developing rheumatoid arthritis: a large-scale cohort study. Immunol Res 2020;68:373-8. [PMID: 33159312 DOI: 10.1007/s12026-020-09160-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
10 Mohamad AF, Iversen L, Bech R. Pemphigus Vulgaris: Short Time to Relapse in Patients Treated in a Danish Tertiary Referral Center. Front Med (Lausanne) 2019;6:259. [PMID: 31850351 DOI: 10.3389/fmed.2019.00259] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
11 Zhao W, Wang J, Zhu H, Pan M. Comparison of Guidelines for Management of Pemphigus: a Review of Systemic Corticosteroids, Rituximab, and Other Immunosuppressive Therapies. Clin Rev Allergy Immunol 2021. [PMID: 34350539 DOI: 10.1007/s12016-021-08882-1] [Reference Citation Analysis]